Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is AstraZeneca the Ultimate Stock Picker's Share?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

LONDON -- I use a market statistics to identify shares for further research. Whatever the market conditions, stock-picking software will always identify a share worth buying.

AstraZeneca  (LSE: AZN  ) (NYSE: AZN  ) is the 12th biggest company in the FTSE 100. It is a true blue chip. According to a large number of investment strategies, the shares should be bought today.

What's to love?
AstraZeneca shares satisfy selection criteria that makes them attractive to three different types of investor. AstraZeneca currently ticks the boxes for value, income, and momentum strategies.

A value play
Investors have long been skeptical of the company's ability to develop new drugs. Perhaps as a result of this, AstraZeneca shares made no progress at all in the three years ending 2012.

Today, AstraZeneca trades on a 2013 P/E of just 9.6 times 2013 forecasts. AstraZeneca's rating is in the bottom 10% of the entire index. Low valuations like that are usually the result of masses of negative sentiment.

If AstraZeneca can convince the markets that its earnings are not about to enter a prolonged decline, then I would expect the shares to rise significantly.

Income credentials
According to the consensus of broker forecasts, AstraZeneca trades on a prospective yield for 2013 of 5.5%. The 2014 forecast dividend yield amounts to an impressive 5.6%. The payout is almost twice covered by earnings, meaning that there is little risk of a cut.

Few companies have a record of paying a dividend of such size. Another factor to attract investors is the fact that AstraZeneca has not cut its dividend in more than ten years.

By my calculations, only Shell is currently cheaper on both a P/E and yield basis.

Strong share price
Many investors won't buy unless they see some signs of share price revival. So far this year, AstraZeneca shares are up 14.1%. That's well ahead of the FTSE 100, which is up 9% in the same period. This upturn in AstraZeneca's share price means that the shares have now come to the attention of momentum investors.

Momentum investors believe that a company's shares are more likely to rise if they have some gains behind them. For AstraZeneca to get back to the kind of rating enjoyed by the average FTSE 100 company, the shares would need to rise more than 30%.

Pharmaceutical shares like AstraZeneca have long been considered a good home for long-term investment. To highlight five more investment opportunities for the long run, our analysts have prepared a free report, "5 Shares To Retire On." This report is totally free and comes with no further obligation. To get our analysts' insights on these five companies, click here to get the report delivered to your inbox immediately.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2393994, ~/Articles/ArticleHandler.aspx, 10/26/2016 9:24:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 18,169.27 -53.76 0.00%
S&P 500 2,143.16 -8.17 0.00%
NASD 5,283.40 -26.43 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 9:08 AM
AZN $4740.50 Down -71.00 -1.48%
AstraZeneca CAPS Rating: No stars
AZN $29.79 Down -0.29 +0.00%
AstraZeneca CAPS Rating: ****